iRhythm Technologies (NASDAQ:IRTC) Director Abhijit Talwalkar Acquires 7,900 Shares of Stock

iRhythm Technologies (NASDAQ:IRTC – Get Free Report) Director Abhijit Talwalkar acquired 7,900 shares of the business’s stock in a transaction on Thursday, November 19th. The shares were bought at an average price of $96.67 per share, for a total transaction of $763,693.00. Following the acquisition, the director owned 7,900 shares in the company, valued at approximately $763,693. This trade represents a ? increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

iRhythm Technologies Trading Down 0.7%

IRTC stock traded down $0.63 during mid-day trading on Thursday, reaching $94.24. 796,125 shares of the stock traded hands, compared to its average volume of 636,414. The company has a current ratio of 3.57, a quick ratio of 3.45 and a debt-to-equity ratio of 3.68. iRhythm Technologies has a 52-week low of $82.85 and a 52-week high of $192.47. The company has a market cap of $3.17 billion, a P/E ratio of -80.55 and a beta of 1.39. The stock’s fifty day moving average is $109.99 and its 200-day moving average is $119.00.

iRhythm Technologies (NASDAQ:IRTC – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.80. The business had revenue of $221.59 million for the quarter, compared to the consensus estimate of $222.23 million. iRhythm Technologies had a negative net margin of 4.52% and a positive return on equity of 26.88%. The firm’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.06) earnings per share. As a group, sell-side analysts expect that iRhythm Technologies will post 0.79 earnings per share for the current year.

iRhythm Technologies announced that its Board of Directors has approved a stock buyback plan on Wednesday, November 11th that permits the company to repurchase $200 million in outstanding shares. This repurchase authorization permits the company to buy up to 6.7% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its shares are undervalued.

Institutional Trading of iRhythm Technologies

A number of hedge funds have recently made changes to their positions in IRTC. Algert Global LLC boosted its stake in shares of iRhythm Technologies by 302.1% during the 3rd quarter. Algert Global LLC now owns 17,743 shares of the company’s stock valued at $2,017,000 after buying an additional 13,330 shares during the period. HighMark Wealth Management LLC purchased a new position in shares of iRhythm Technologies during the 3rd quarter valued at $40,000. Schwarz Investment Partners Inc. acquired a new position in shares of iRhythm Technologies in the third quarter worth $34,000. Bamco Inc. NY increased its stake in shares of iRhythm Technologies by 27.1% in the third quarter. Bamco Inc. NY now owns 230,618 shares of the company’s stock worth $26,212,000 after acquiring an additional 49,188 shares during the last quarter. Finally, Jump Financial LLC acquired a new position in shares of iRhythm Technologies in the third quarter worth $15,497,000.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Piper Sandler lowered their price objective on shares of iRhythm Technologies from $160.00 to $150.00 and set an “overweight” rating on the stock in a research report on Friday, November 6th. BTIG Research reduced their target price on iRhythm Technologies from $185.00 to $170.00 and set a “buy” rating for the company in a report on Friday, November 6th. Citigroup lowered iRhythm Technologies from a “buy” rating to a “neutral” rating and reduced their target price for the company from $157.00 to $124.00 in a report on Friday, November 6th. Weiss Ratings cut iRhythm Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, November 12th. Finally, Truist Financial lowered their price target on iRhythm Technologies from $168.00 to $140.00 and set a “buy” rating on the stock in a report on Monday, November 9th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $164.07.

Read Our Latest Stock Analysis on IRTC

iRhythm Technologies Company Profile

(Get Free Report)

iRhythm Technologies is a medical technology company that develops digital solutions for detecting and monitoring heart rhythm disorders. Its services combine wearable electrocardiogram (ECG) devices with cloud-based data analysis and clinical reporting to help healthcare professionals assess patients for conditions such as cardiac arrhythmias. The company’s Zio product line includes wearable ECG monitors, such as Zio XT, which records a patient’s heart activity during an extended monitoring period. iRhythm also offers Zio AT, a monitoring service designed to provide clinicians with ECG data during the monitoring period.

Featured Stories

Insider Buying and Selling by Quarter for iRhythm Technologies (NASDAQ:IRTC)

Receive News & Ratings for iRhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.